Beta-amino Pateamine A Derivatives for CLL Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current β-amino pateamine A derivatives face challenges with therapeutic effectiveness, toxicity, and pharmacokinetic properties, particularly high plasma protein binding which reduces their potency and bioavailability, limiting their potential as effective therapeutic agents for chronic lymphocytic leukemia (CLL).
Innovation Solution
Development of β-amino pateamine A derivatives with specific structural modifications, such as introducing an amino group at the C2 or C3 position, which reduces plasma protein binding and enhances potency, combined with antibody drug conjugates for targeted delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If DMDAPatA is used to inhibit cap-dependent translation initiation, then anti-proliferative activity against cancer cells is improved, but plasma protein binding increases which reduces in vivo potency
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of DMDAPatA through introducing amino groups at C2 or C3 positions and creating amide derivatives. These structural parameter changes reduce plasma protein binding while preserving anti-proliferative activity against CLL cells
Solution Approach 2:
The patent creates composite therapeutic approaches by combining β-amino pateamine A derivatives with antibody drug conjugates (such as anti-CD20 antibody conjugates). This composite strategy enables targeted delivery to CLL cells while reducing off-target effects and improving therapeutic index
2Reliability
If PatA derivatives are developed to improve therapeutic effectiveness, then anti-CLL activity is enhanced, but toxicity to normal cells increases
Solution Approach 1:
The patent applies local quality by creating antibody drug conjugates where the cytotoxic β-amino pateamine A derivative is selectively delivered to CLL cells expressing specific surface markers (such as CD20). This localized delivery spares normal lymphocytes from toxicity while maintaining potent anti-CLL activity
Solution Approach 2:
The patent uses antibody intermediaries (such as anti-CD20 antibodies) to mediate selective delivery of the cytotoxic derivative to target cells. The antibody acts as a mediator that recognizes CLL cells specifically, reducing off-target toxicity to normal lymphocytes
3Quantity of substance
If structural modifications are introduced to reduce plasma protein binding, then bioavailability is improved, but molecular complexity increases
Solution Approach 1:
The patent applies parameter changes by introducing amino groups at specific positions (C2 or C3) and creating amide derivatives with controlled substitution patterns. These targeted structural parameter changes reduce plasma protein binding and improve bioavailability while maintaining reasonable molecular complexity through systematic modification rather than random complexity increase
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The modified β-amino pateamine A derivatives demonstrate potent inhibitory activity against CLL cells with reduced plasma protein binding, offering improved bioavailability and therapeutic potential, including synergy with existing therapies like ABT-199, and reduced toxicity to normal lymphocytes.
Implementation Method 1
PatA and DMDAPatA inhibit cap-dependent translation initiation by sequestration of eIF4A that prevents formation of the eIF4F complex
Data Source
Figure 1
Figure 2
Figure 3A~3B
AI summary
Pateamine A derivatives, pharmaceutical compositions that include the derivatives, and methods for treating chronic lymphocytic leukemia using the derivatives.